Quick Answer
REGENXBIO Inc. reported Operating Income Loss of -$161.20 million for the year ending 2025.
- REGENXBIO Inc. showed an increase of +30.9% in Operating Income Loss from 2024 to 2025.
- This data is from REGENXBIO Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), REGENXBIO Inc.'s Operating Income Loss has declined by 3,275.2%.
- Historical annual values: Fiscal year 2025: -$161.20 million | Fiscal year 2024: -$233.35 million | Fiscal year 2023: -$268.13 million | Fiscal year 2022: -$262.88 million | Fiscal year 2021: $159.98 million | Fiscal year 2020: -$119.23 million | Fiscal year 2019: -$149.00 million | Fiscal year 2018: $88.10 million | Fiscal year 2017: -$75.89 million | Fiscal year 2016: -$65.34 million | Fiscal year 2015: -$23.14 million | Fiscal year 2014: -$3.68 million | Fiscal year 2013: -$4.78 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: